Social Psychiatry and Psychiatric Epidemiology

, Volume 46, Issue 12, pp 1325–1330 | Cite as

Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study

  • Yu-Tao Xiang
  • Chuan-Yue Wang
  • Yong-Zhen Weng
  • Qi-Jing Bo
  • Helen F. K. Chiu
  • Sandra S. M. Chan
  • Edwin H. M. Lee
  • Gabor S. Ungvari
Original Paper



Relapse prevention is the main goal of maintenance treatment in schizophrenia. This study aimed to determine the rate and the socio-demographic and clinical predictors of relapse in Chinese schizophrenia patients following treatment of the acute phase of the illness.


In a multi-center, randomized, controlled, longitudinal study, 404 patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to either the maintenance (i.e., initial optimal therapeutic doses continued throughout the study) or the dose-reduction group (i.e., initial optimal therapeutic doses continued for 4 or 26 weeks followed by a 50% dose reduction that was maintained until the end of the study). Participants were interviewed at entry using standardized assessment instruments, and followed up for 12–26 months.


In univariate analyses, relapse was significantly associated with the membership of the dose-reduction group, poor medication adherence, and having a diagnosis of the paranoid type of schizophrenia. In Cox proportional-hazards regression analysis the membership of the dose-reduction group, poorer medication adherence, more severe drug-induced side effects and prominent paranoid symptoms independently predicted a higher risk of relapse.


The study confirmed the importance of maintenance medication in preventing relapse in Chinese schizophrenia patients underscoring the risk of relapse associated with lack of treatment adherence, severe side effects and the patients’ paranoid attitude. Socio-demographic characteristics were not associated with relapse in Chinese schizophrenia patients. Potential residual confounding caused by unmeasured variables should be fully considered in future studies.


Schizophrenia Maintenance treatment Relapse Paranoid China 



This study was supported by grants from the 10th National Five-Year Plan Foundation of the Ministry of Science and Technology Program, People’s Republic of China (No. 2004BA720A22), the Research Foundation of the Xian-Janssen Pharmaceutical Company (No. RIS-CN-MCCT-0201), the National Natural Science Foundation of China (No. 30800367), and the Beijing Nova Program of the Beijing Municipal Science and Technology Commission (No. 2008B59).

Conflict of interest



  1. 1.
    Gaebel W, Riesbeck M (2007) Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res 95:19–29PubMedCrossRefGoogle Scholar
  2. 2.
    Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884–897PubMedCrossRefGoogle Scholar
  3. 3.
    Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21:419–429PubMedGoogle Scholar
  4. 4.
    Hugenholtz GW, Heerdink ER, Meijer WE, Stolker JJ, Egberts AC, Nolen WA (2005) Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 38:122–124PubMedCrossRefGoogle Scholar
  5. 5.
    Rantanen H, Koivisto AM, Salokangas RK, Helminen M, Oja H, Pirkola S, Wahlbeck K, Joukamaa M (2009) Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization. Soc Psychiatry Psychiatr Epidemiol 44:135–142PubMedCrossRefGoogle Scholar
  6. 6.
    Chen EY, Hui CL, Dunn EL, Miao MY, Yeung WS, Wong CK, Chan WF, Tang WN (2005) A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res 77:99–104PubMedCrossRefGoogle Scholar
  7. 7.
    Xiang Y, Weng Y, Li W, Gao L, Chen G, Xie L, Chang Y, Tang WK, Ungvari GS (2006) Training patients with schizophrenia with the community re-entry module: a controlled study. Soc Psychiatry Psychiatr Epidemiol 41:464–469PubMedCrossRefGoogle Scholar
  8. 8.
    Beiser M, Bean G, Erickson D, Zhang J, Iacono WG, Rector NA (1994) Biological and psychosocial predictors of job performance following a first episode of psychosis. Am J Psychiatry 151:857–863PubMedGoogle Scholar
  9. 9.
    Doering S, Muller E, Kopcke W, Pietzcker A, Gaebel W, Linden M, Muller P, Muller-Spahn F, Tegeler J, Schussler G (1998) Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 24:87–98PubMedGoogle Scholar
  10. 10.
    Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52:173–188PubMedGoogle Scholar
  11. 11.
    Hershon HI, Kennedy PF, McGuire RJ (1972) Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br J Psychiatry 120:41–50PubMedCrossRefGoogle Scholar
  12. 12.
    Jonsson H, Nyman AK (1991) Predicting long-term outcome in schizophrenia. Acta Psychiatr Scand 83:342–346PubMedCrossRefGoogle Scholar
  13. 13.
    Mortensen PB, Eaton WW (1994) Predictors for readmission risk in schizophrenia. Psychol Med 24:223–232PubMedCrossRefGoogle Scholar
  14. 14.
    Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241–247PubMedCrossRefGoogle Scholar
  15. 15.
    Zander KJ, Fischer B, Zimmer R, Ackenheil M (1981) Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal. Psychopharmacology (Berl) 73:43–47CrossRefGoogle Scholar
  16. 16.
    Scottish Schizophrenia Research Group (1992) The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings. Br J Psychiatry 161:496–500CrossRefGoogle Scholar
  17. 17.
    Cheng XG, Xu H (2001) Analyses on related factors in relapse of schizophrenics (in Chinese). Mod Rehabil 5:30–31Google Scholar
  18. 18.
    Ding LJ (2007) Correlates of relapse in schizophrenia patients (in Chinese). Med J Chin People Health 19:481–482Google Scholar
  19. 19.
    Huang LG, Ye P, Zhu CF (2006) Comparison of risk factors of relapse in schizophrenia patients between urban and rural areas (in Chinese). Med J Chin People Health 18:203–204Google Scholar
  20. 20.
    Jia XS (2006) Analyses on factors of relapse in 579 rehospitalized schizophrenic patients (in Chinese). J Clin Psychosom Disord 12:243–244Google Scholar
  21. 21.
    Jiang LP (2004) Correlates of relapse in first-episode schizophrneia patients (in Chinese). Chin J Health Psychol 12:368–369Google Scholar
  22. 22.
    Meng YL, Guo H (2008) Related factor analysis on 98 re-onset patients with schizophrenia (in Chinese). Chin J Health Psychiatry 16:128–129Google Scholar
  23. 23.
    Xu ML, Peng HY (1997) Multiple factors for relapse in schizophrenia patients (in Chinese). Zhongyuan Mental Health 3:73–75Google Scholar
  24. 24.
    Zhang LP (2008) The study on clinical high risk factors of intractable schizophrenia (in Chinese). World Health Digest 5:240–242Google Scholar
  25. 25.
    Hu SF, Han XL, Yang QL, Wu XQ (2000) Risk factor for relapse in schizophrenia patients (in Chinese). Chin J Nerv Ment Dis 26:298–299Google Scholar
  26. 26.
    Liu TQ, Yang DS, Wang XP, Hao W (2000) Factors associated with schizophrenic relapse: one year follow-up study (in Chinese). Chin J Nerv Ment Dis 26:265–267Google Scholar
  27. 27.
    Weng YZ, Xu MJ, Li DL, Guo FY, Huang Q, Fu T (2001) Assessment of expressed emotion in family members of schizophrenic patients in Beijing. Mod Rehabil 5:39–42Google Scholar
  28. 28.
    Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, Liu TQ, Wang GH, Weng SM, Zhang HY, Chen DF, Tang WK, Ungvari GS (2010) Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 167:676–685PubMedCrossRefGoogle Scholar
  29. 29.
    Altman DG, Schulz KF (2001) Statistics notes: concealing treatment allocation in randomised trials. BMJ 323:446–447PubMedCrossRefGoogle Scholar
  30. 30.
    Csernansky JG, Mahmoud R, Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16–22PubMedCrossRefGoogle Scholar
  31. 31.
    He YL, Zhang MY (1997) The positive and negative syndrome scale (PANSS) and its application (in Chinese). J Clin Psychiatry 7:353–355Google Scholar
  32. 32.
    Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538–546PubMedCrossRefGoogle Scholar
  33. 33.
    National Institute of Mental Health (1985) TESS (Treatment Emergent Symptom Scale-Write-in). Psychopharmacol Bull 21:1069–1072Google Scholar
  34. 34.
    Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S (2005) Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 66:1021–1030PubMedCrossRefGoogle Scholar
  35. 35.
    Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222PubMedCrossRefGoogle Scholar
  36. 36.
    Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE (2003) Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 160:1405–1412PubMedCrossRefGoogle Scholar
  37. 37.
    Lipkovich I, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, Zhang Y, Liu-Seifert H, Houston JP (2007) Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. J Psychiatr Res 41:305–310PubMedCrossRefGoogle Scholar
  38. 38.
    McCann TV, Boardman G, Clark E, Lu S (2008) Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs 15:622–629PubMedCrossRefGoogle Scholar
  39. 39.
    Zhang J, LU Z (2008) Correlates of relapse in schizophrenia patients (in Chinese). Shanghai Arch Psychiatry 20:811–813Google Scholar
  40. 40.
    Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM (2004) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30:193–217PubMedGoogle Scholar
  41. 41.
    Kampman O, Lehtinen K (1999) Compliance in psychoses. Acta Psychiatr Scand 100:167–175PubMedCrossRefGoogle Scholar
  42. 42.
    Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS (2009) Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs 23:171–180PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yu-Tao Xiang
    • 1
    • 2
  • Chuan-Yue Wang
    • 1
    • 4
  • Yong-Zhen Weng
    • 1
  • Qi-Jing Bo
    • 1
  • Helen F. K. Chiu
    • 2
  • Sandra S. M. Chan
    • 2
  • Edwin H. M. Lee
    • 2
  • Gabor S. Ungvari
    • 3
  1. 1.Beijing Anding Hospital, Capital Medical UniversityBeijingChina
  2. 2.Department of PsychiatryChinese University of Hong KongHong KongChina
  3. 3.School of Psychiatry & Clinical Neurosciences, University of Western AustraliaPerthAustralia
  4. 4.Laboratory of Clinical PsychopharmacologyBeijing Anding HospitalBeijingChina

Personalised recommendations